



Original Paper

Characterization of some antimicrobial genes of *Escherichia coli* recovered from pet animals and human with urinary tract infections

Ashraf, A. Abd El Tawab¹; Ahmed, A. A. Maarouf²; Nermin, Essa¹; Emad E. El-Mougy² and Wedad, Ahmed¹

¹Department of Bacteriology, Immunology and Mycology, Benha University, Faculty of Veterinary Medicine, Egypt.

²Animal Health Research Institute "Benha branch" ARC.

ARTICLE INFO

Keywords

*Uropathogenic
Escherichia coli
pet animals*

Antimicrobial genes

Received 01/09/2022

Accepted 27/09/2022

Available On-Line

09/10/2022

ABSTRACT

The present study is directed to isolate and identify pathogenic *E. coli* from urine of humans and pet animals (dogs and cats) suffering from urinary tract infections (UTIs) who admitted to different hospitals and veterinary clinics (35 for each), at Kaliobia Governorate and to determine their antimicrobial sensitivity, beside detection of some resistance genes. The results revealed that, that *E. coli* were isolated from 41 from the examined samples where, (15/42.9%) from human; (14/40.0%) and (12/34.3 %) from dogs and cats urine samples, respectively. The isolated *E. coli* were highly sensitive to meropenem followed by nitrofurantoin; norfloxacin and gentamycin. Meanwhile, they were highly resistant to nalidixic acid followed by ampicillin; tetracycline; cefotaxime; azithromycin; co-trimoxazole; streptomycin and ciprofloxacin. Moreover, PCR results showed that, *qnrS*; *aadA1* and *blaTEM* antibiotic resistant genes were amplified in all sex studied *E. coli* strains and *mphA* resistant gene was amplified in five studied strains. Therefor, the study concluded that, uropathogenic *E. coli* of humans, dogs and cats affected with UTIs may be the most important pathogen with multiple antibiotic resistances and there were positive correlation between the presence of *qnrS*; *mphA*; *aadA1* and *blaTEM* genes in these strains with the phenotypic resistance to the antibiotics of these groups.

1. INTRODUCTION

Escherichia coli is a predominant pathogen causing urinary tract infections in humans and pet animals (Ramirez-Castillo *et al.*, 2018 and Mustapha *et al.*, 2019). It belongs to the family *Enterobacteriaceae* and is Gram negative, non-sporulating, flagellated, rod-shaped, and facultatively anaerobic (it grows best at 37 °C but can tolerate 49 °C. Jang *et al.*, 2017). While UTIs are treatable, rising incidence of multi-drug resistance organisms (MDRO) such as *E. coli* cause complications, treatment failure, and a rise in mortality and morbidity (Mustapha *et al.*, 2019). UPEC has a wide range of virulence factors, including adhesins, toxins, host defense avoidance mechanisms, and iron acquisition systems, which they use to create an infection (Ramirez-Castillo *et al.*, 2018). Most of the community acquired UTIs and half of nosocomial UTIs are caused by different pathotypes of UPEC. Both chromosomal and plasmid-encoded antibiotic resistance and virulence genes in UPEC have been identified (Momtaz *et al.*, 2013; Abbasi and Ranjbar, 2018). The limited number of effective medications available to treat these infections is made more difficult by the rise of multidrug-resistant (MDR) UPEC. The most important factor in the development of antibiotic resistance in UPEC was identified as the presence of genes encoding resistance to quinolones (*qnrS*), macrolide phosphotransferases

(*mphA*), streptomycin (*aadA1*), and lactamase (*blaTEM*) by the molecular studies (Momtaz *et al.*, 2013; Rzewuska *et al.*, 2015; Salehi *et al.*, 2021 and Belas *et al.*, 2022). The pathogenicity of bacteria, its global distribution, its capacity to colonize and persist in the hosts for more than 6 months, its capacity for transmission between hosts, and its ability to cause recurrent infections are all linked with the classification as an international MDR high-risk clonal lineage, in addition to the association with various antimicrobial resistance determinants. In addition, the dissemination of *qnrS* among Gram-negative bacteria like UPEC and the transmission of quinolone resistant genes (*qnr*) that are mediated by plasmids are major concerns for the international health care system (Abbasi and Ranjbar, 2018). There are several potential mechanisms by which *Enterobacteriaceae*, and particularly UPEC, develop resistance to macrolides like erythromycin and azithromycin. methylases, notably *ermA* and *ermB*, from the *erm* gene family displace the target site, inactivating enzymes like esterase from the *ere* (A) and *ere* (B) genes or phosphotransferases from the *mphA* gene family (Salehi *et al.*, 2021). As a result of the increased prevalence and global spread of extended-spectrum beta-lactamase (ESBL) genes like CTX-M, TEM enzymes that are associated to multidrug-resistant (MDR) phenotypes of UPEC and other Uropathogens exhibiting resistance to most antibiotics, MDR phenotypes have become

* Corresponding author: nyrmyny594@gmail.com

increasingly common (Windahl et al., 2014; Ramirez-Castillo et al., 2018; Alasmary, 2021; Said et al., 2021 and Belas et al., 2022).

The purpose of this investigation was to extract and identify pathogenic *E. coli* from UTI-affected human and canine (dog and cat) urine, as well as to discover certain gene resistance utilizing standard Polymerase Chain Reaction (PCR).

2. MATERIAL AND METHODS

2.1. Samples:

Total of 105 (10 ml of freely voided middle stream urine samples or by catheterization from the urethra) were collected in sterile screw capped tubes diseased human patients and pet animals (dogs and cats) with urinary tract infections, (35 for each), who admitted to different hospitals and veterinary clinics at Kaliobia Governorate according to Yadav et al., (2020). The urine samples were centrifuged at 3000 Xg and the supernatant were aseptically discarded while the sediments were used for *E. coli* isolation.

2.2. The method of Iso, 2001 & Markey et al. 2013 was applied in Isolation and identification of *E. coli* from urine samples:

After 12 hours of aerobic incubation at 37°C, a loopful of urine sediment was inoculated into nutritional broth. To do this, we took a loopful of the nutritional broth and streaked it onto MacConkey agar plates, where it was incubated at 37°C for 24 hours. Colonies that showed signs of lactose

Antimicrobial standardized discs, concentrations, and interpretation of their effect (CLSI, 2018).

fermentation were picked and streaked onto Eosin methylene blue media (EMB) and TBX agar, where they were incubated for an additional 24-48 hours at 37°C before being examined. These colonies appeared to be *E. coli*, (colonies with a bright green sheen on EMB and blue colonies on TBX agar B- glucuronidase positive) were. Suspected *E. coli* colonies were confirmed morphologically by Gram- stain, Gram- negative, straight, non- sporulated, medium size rods arranged singly in pairs or short chain colonies were selected for further identification steps and motility tests, by stabbing the bacterial isolate in the center of 0.5% Semi-solid agar tubes then incubated at 37°C for 24 hrs. (*E. coli* isolates were motile and seen to spread from point of inoculation into the agar as paintbrush). Then, they were identified biochemically by indole; methyl red; Voges-Proskauer; citrate utilization; urease test; Eijkman; catalase; oxidase; Sugar fermentation; nitrate reduction and gelatin hydrolysis tests.

In-Vitro anti-microbial sensitivity test:

In-Vitro sensitivity test was done on each *E. coli* isolates to study their sensitivity for 14 different antimicrobial using the antimicrobial standardized discs (Oxoid), {amoxicillin/clavulanic acid(AMC/30); ampicillin (AM/10); azithromycin (AZM/15); cefotaxime (CTX/30); ciprofloxacin (CIP/5); co-trimoxazole (COT/25); doxycycline (DO/30); gentamicin (GEN/10); Meropenem (MEM/10); Naledixic acid (NA/30); Nitrofurantion (F/300); norfloxacin (NOR/10); streptomycin (S/10) and tetracycline (TE/30)} on Mueller-Hinton agar (Oxoid) plates and following disc method of CLSI (2018).

Antimicrobial disks	Disk Concentrations	Zone of inhibition(mm)		
		Resistant ≤ mm (R)	Intermediate mm range (IS)	Sensitive ≥ mm (S)
Amoxicillin/ clavulanic acid	AMC	30 µg	13	14 -17
Ampicillin	AM10	10 µg	13	14-16
Azithromycin	AZM	15 µg	13	14-17
Cefotaxime	CTX/30	30 µg	14	15-22
Ciprofloxacin	CIP/5	5 µg	15	16-20
Co- Trimoxazole	COT/25	(1.25/23.75) µg	10	11-15
Doxycycline	Do 30	30 µg	14	15-19
Gentamicin	GEN/10	10 µg	12	13-14
Meropenem	MEM	10 µg	14	15-19
Nalidixic acid	NA/ 30	30 µg	13	14-18
Nitrofurantion	F/300	300 µg	14	15-16
Norfloxacin	NOR/10	10 µg	12	13-16
Streptomycin	S/10	10 µg	11	12-14
Tetracycline	TE/30	30 µg	14	15-18

2.3. Molecular detection of antibiotic resistant genes of *E. coli*:

Genotypic detection of four antibiotic resistant genes, quinolones resistant gene (*qnrS*); macrolide phosphotransferases resistance (*mphA*); streptomycin resistant gene (*aadA1*) and β-lactamase resistance gene (*blaTEM*) in sex random *E. coli* (two from each sample of human; dogs and cats urine samples) that showed antibiotic resistant by disk diffusion method to the same studied

isolates using conventional polymerase chain reaction (cPCR), Primers sequences, target genes, amplicons sizes, and cycling conditions were determined by running PCR reactions with the specified primers and amplification products on 1.5% agarose gels in accordance with the instructions provided by QIAamp® DNA Mini Kit (Qiagen, Germany, GmbH) using Emerald Amp GT PCR mastermix (Takara, Japan) showed through Table (1).

Table 1 Primers sequences, target genes, amplicons sizes and cycling conditions.

Target gene		Primer sequence (5'-3')	Amplified segment (bp.)	Primary denaturation	Secondary denaturation	Amplification (35 cycles)	Final extension	References
<i>qnrS</i>	F	ACGACATTCTGCAACT GCAA	516 bp.	94°C 5 min.	94°C 30 sec.	55°C 40 sec	72°C 45sec.	72°C 10min.
	R	TAAATTGGCACCCGT AGGC						Robicsek et al. (2006)
<i>mphA</i>	F	GTGAGGAGGAGCTTC GCGAG	403 bp.	94°C 5 min.	94°C 45 sec.	58°C 40 sec	72°C 40 sec	Nagyuen et al. (2009)
	R	TGCCGCAGGACTCGG AGGTC						
<i>aadA1</i>	F	TATCAGAGGTAGTT GCGTCAT	484bp.	94°C 5 min.	94°C 30 sec.	54°C 40 sec.	72°C 45 sec.	Randall et al. (2004)
	R	GTTCCATAGCGTTAAG GTTTCATT						
<i>blaTEM</i>	F	ATCAGCAATAAACCA GC	516bp.	94°C 5 min.	94°C 30 sec.	54°C 40 sec.	72°C 45 sec.	Colom et al. (2003)
	R	CCCCGAAGAACGTTT C						

3. RESULTS

The results of bacteriological examination of urine samples (Table, 2) cleared that, 41 *E. coli* (39.1%) isolates were recovered from 105 urine samples affected with UTIs; they were isolated from human urine (15/42.9%); dog's urine (14/40.0%) and cat's urine samples (12/34.3%).

Table 2 Prevalence of isolated *Escherichia coli* bacteria from different urine samples.

Urine sample species	Number of sample	Negative samples No.	%	Positive samples No.	%
Human with UTIs	35	20	57.1	15	42.9
Dogs with UTIs	35	21	60.0	14	40.0
Cats with UTIs	35	23	65.7	12	34.3
Total	105	64	60.9	41	39.1

* Percentage in relation to total No. of each examined urine sample (35 & 105 for total)

Phenotypically, it seems that *E. coli* isolates are Gram-negative, medium-sized rods that are solitary, in pairs, or in small groups, but do not produce spores. On Nutrient agar, their colonies appeared as round, non-pigmented

bumps, but on MacConkey agar, their colonies appeared as round, non-mucoid brilliant pink bumps (lactose fermenter). The identical isolates displayed the normal blue colonies on TBX agar, but the EMB agar colonies had a characteristic greenish metallic shine (B-glucuronidase positive). Further, all 41 isolates exhibited positive findings in the indole test, Methyl red test, catalase test, sugar fermentation test, nitrate reduction test, and Eijkman test, indicating that they were all *E. coli*. They also tested negative for the enzyme oxidase. The gelatin hydrolysis, urease, citrate utilization, and Voges-Proskauer tests.

The results of *in-vitro* sensitivity tests for the isolated *E. coli* are tabulated in (Table, 3) as the following:

In table (3) there was a significant decrease ($P < 0.0001$) in AST (69.11 ± 2.71 and 67.35 ± 1.03), ALT (18.49 ± 0.80 and 16.44 ± 0.78) and AKP (16.48 ± 0.84 and 14.63 ± 1.10) levels in the kaempferol treated semen samples mainly those supplemented with 25 and 50 μ g/ml, respectively if compared with control group (106.0 ± 2.17 , 28.09 ± 1.11 and 25.86 ± 0.52 , respectively).

Table 3 In-Vitro anti-microbial sensitivity test for isolated 41 isolated *E. coli*.

Antimicrobial agents	Disk concentrations	Sensitive		Intermediate		Resistant		AA	
		No.	%	No.	%	No.	%		
Meropenem	MEM	10 μ g	37	90.2	4	9.8	0	0.0	S
Nitrofurantion	F/300	300 μ g	31	75.6	8	19.5	2	4.9	S
Norfloxacin	NOR/10	10 μ g	30	73.2	8	19.5	3	7.3	S
Gentamicin	GEN/10	10 μ g	27	65.8	4	9.8	10	24.4	S
Amoxicillin/clav ulanic acid	AMC	30 μ g	7	17.1	24	58.5	10	24.4	IS
Doxycycline	DO	30 μ g	8	19.5	22	53.7	11	26.8	IS
Nalidixic acid	NA/30	30 μ g	0	0.0	7	17.1	34	82.9	R
Ampicillin	AM10	10 μ g	2	4.9	6	14.6	33	80.5	R
Tetracycline	TE/30	30 μ g	3	7.3	5	12.2	33	80.5	R
Cefotaxime	CTX/30	30 μ g	3	7.3	7	17.1	31	75.6	R
Azithromycin	AZM	15 μ g	4	9.8	8	19.5	29	70.7	R
Co- Trimoxazole	COT/25	(1.25/23.75) μ g	6	14.6	9	22.0	26	63.4	R
Streptomycin	S/10	10 μ g	3	7.3	14	34.2	25	58.5	R
Ciprofloxacin	CIP/5	5 μ g	7	17.1	11	26.8	23	56.1	R

No.: Number of isolates AA: Antibiogram activity

%: Percentage in relation to total number of *E. coli* isolates (n=41)

The results of genotyping detection of antibiotic resistant genes, showed that, *qnrS*; *aadA1* and *blaTEM* antibiotic resistant genes were amplified in all sex studied *E. coli* strains giving products of 516 bp.; 484 bp. and 516 bp., respectively (Figures, 1 and 2). Meanwhile, *mphA* resistant gene was amplified in five studied *E. coli* strains giving product of 403 bp. but not amplified in one *E. coli* strain of cat urine (Fig. 1).




Figure 1 quinolones resistant (*qnrS*) gene. Lane L: 100-1000 bp. DNA Ladder. Neg: Negative control. (*S. aureus* ATCC25923) Pos.: Positive control (*E. coli* form Ahri. at 516 bp.). Lane 1- 6: Positive *E. coli* at 516 bp. (1&2 human urine; 3&4dogs urine and 5&6 cats' urine) Fig. (1-b): Macrolide phosphotransferases resistance (*mphA*) gene. Lane L: 100-1000 bp. DNA.

Neg.: Negative control. (*S. aureus* ATCC25923) Pos.: Positive control (*E. coli* form Ahri. at 403 bp.). Lane1- 4 & 6: Positive *E. coli* at 403 bp. (1&2 human urine; 3&4dogs urine and 6 cats' urine) Lane 5: Negative *E. coli* at 403 bp. (cat urine).




Figure 2 Streptomycin resistant (*aadA1*) gene. Lane L: 100-1000 bp. DNA Ladder. Neg.: Negative control. (*S. aureus* ATCC25923) Pos.: Positive control (*E. coli* form Ahri. at 516 bp.). Lane 1- 6: Positive *E. coli* at 484 bp. (1&2 human urine; 3&4dogs urine and 5&6 cats' urine) Fig. (2-b): β -lactamase resistance (*blaTEM*) gene. Lane L: 100-1000 bp. DNA. Neg.: Negative control (*S. aureus* ATCC25923) Pos.: Positive control (*E. coli* form Ahri. at 516 bp.) Lane 1- 6: Positive *E. coli* at 516 bp. (1&2 human urine; 3&4dogs urine and 5&6 cats' urine).

4. DISCUSSION

The present study revealed that, 41 *E. coli* isolates (39.1%) were obtained from 105 urine samples affected with UTIs; they were isolated from human urine (15/42.9%); dog's urine (14/40.0%) and cat's urine samples (12/34.3%). The recorded results for human patients nearly similar to those of Ghavide *et al.* (2020); Mahdi *et al.* (2020) and Said *et al.* (2021). For dog, the results came in constant with chang *et al.* (2015); Liu *et al.* (2017); Moyaert *et al.* (2017); Mustapha *et al.* (2019) and Fonseca *et al.* (2021). Meanwhile, the results of UPEC in cats urine came in harmony with Dorsch *et al.* (2015); Moyaert *et al.* (2017) and Fonseca *et al.* (2021).

Regarding to the colonial appearance *E. coli* isolated, they appeared as round, non-pigmented bumps on Nutrient agar, but on MacConkey agar, their colonies appeared as round, non-mucoid brilliant pink bumps (lactose fermenter). The identical isolates displayed the normal blue colonies on TBX agar, but the EMB agar colonies had a characteristic greenish metallic shine (B- glucuronidase positive). Further, all 41 isolates exhibited positive findings in the indole test, Methyl red test, catalase test, sugar fermentation test, nitrate reduction test, and Eijkman test, indicating that they were all *E. coli*. They also tested negative for the enzyme oxidase. The gelatin hydrolysis, urease, citrate utilization, and Voges-Proskauer tests. Similar results were recorded by Markey *et al.*, 2013; Mustapha *et al.* (2019) and Said *et al.* (2021). Antibiotic resistance can arise for a number of reasons, including incorrect dosing, overuse, and failure to finish the full course of treatment for a variety of infections, as well as the acquisition of resistance in low-susceptibility bacteria through selection/spontaneous mutation, the development of resistance in enteric bacteria via R plasmids responsible for multiple drug resistance, and the transmission of resistant strains between humans and animals (Setu *et al.*, 2016 and Mustapha *et al.*, 2019). The recorded results in this study for antimicrobial sensitivity of 41 studied uropathogenic *E. coli* isolates (Table 3) cleared that, they were highly resistant for Nalidixic acid followed by ampicillin and tetracycline; cefotaxime; azithromycin; co-trimoxazole; streptomycin and ciprofloxacin. But they were intermediate sensitive to amoxicillin/clavulanic acid and doxycycline, but they were highly sensitive to meropenem; Nitrofurantoin; norfloxacin and gentamycin, with lower resistant for these antimicrobial agents. Nearly similar results were obtained by Raeispour and Ranjbar, 2018;

Alzahrani *et al.* (2020); Ghavide *et al.* (2020); Mahdi *et al.* (2020); Salehi *et al.*, 2021; and Said *et al.* (2021) for human UPEC. Meanwhile, these results for dog UPEC strains came in harmony with windahl *et al.* (2014); Chang *et al.* (2015); McMeekin *et al.* (2016); Liu *et al.* (2017); Moyaert *et al.* (2017); Mustapha *et al.* (2019) and Fonseca *et al.* (2021). Moreover, the results agree with those of Harada *et al.* (2012); Moyaert *et al.* (2017) and Fonseca *et al.* (2021) for cats UPEC. The recorded results proved that, phenotypic multiple antibiotic resistances (MDR) are widely spread among 41 studied uropathogenic *E. coli* isolates, drug-resistance of *E. coli* was not related to its source origin and decided the facts of Ramirez-Castillo *et al.* (2018); Mustapha *et al.* (2019) and Salehi *et al.* (2021) who reported that UPEC strains had MDR whatever their sources and they could be transferred between dogs; cats and humans through direct contact.

Bacterial drug resistance may be both inherited and acquired. Hereditary resistance (whether chromosomal or plasmid-based) occurs when a cell's inherent and inherited features impede the actions of antibiotics, leading to the selection of resistant strains from a population of initially susceptible bacteria (Mortazavi- Tabatabaei *et al.*, 2019). In Egypt, a few studies on *E. coli* resistance have been described in the literatures, focusing on presence of genes related to the production of quinolones, macrolides, streptomycin and β -lactamase resistant genes. The results of PCR appeared that, *qnrS*; *aadA1* and *blaTEM* antibiotic resistant genes were amplified in all sex studied *E. coli* strains but *mphA* resistant gene was amplified in five strains, where quinolones resistant gene (*qnrS*) was amplified at 516 bp. (Fig., 1- a); macrolide phosphotransferases resistance (*mphA*)was amplified at 403 bp. (Fig.,1- b); streptomycin resistant gene (*aadA1*) was amplified at 484 bp. (Fig., 2- a) and β - lactamase resistance gene (*blaTEM*)was amplified at 516 bp. (Fig., 2- b). Similar detection of these genes in UTIEC strains isolated from urine samples of human; dogs and cats were recorded by Rezazadeh *et al.* (2016); Abbasi and Ranjbar (2018) and Ramirez-Castillo *et al.* (2018) for *qnrS* gene; Nguyen *et al.* (2009); and Salehi *et al.* (2021) for *mphA* gene; Randall *et al.* (2004) and Momtaz *et al.*(2013) for *aadA1* gene; Ramirez-Castillo *et al.*(2018) and Belas *et al.*(2022) for *blaTEM* gene.

5. CONCLUSION

The results of this study concluded that, *E. coli* isolated from urine of humans, dogs and cats affected with UTIs may be the most important pathogen that had antimicrobial resistance to most antimicrobial drugs (MDR) and they could be transferred between dogs; cats and humans through direct contact. Moreover, there were positive correlation between the presence of *qnrS*; *mphA*; *aadA1* and *blaTEM* genes in these strains with the phenotypic resistance to the antibiotics of these groups and it would be better to use meropenem; Nitrofurantion; norfloxacin and gentamycin in treating urinary tract infections in human; dogs and cats.

6. REFERENCES

1. Abbasi, H. and Ranjbar, R. (2018): The prevalence of quinolone resistance genes of A, B, S in Escherichia coli strains isolated from three major hospitals in Tehran, Iran. Cent European J Urol. 71(1): 129–133.
2. Alasmary, M.Y. (2021): Antimicrobial Resistance Patterns and ESBL of Uropathogens Isolated from

- Adult Females in Najran Region of Saudi Arabia. *Clin Pract.*, 11(3): 650–658.
3. Alzahrani, M.A.; Ali, M.S. and Sirajudheen Anwar, S. (2020): Bacteria Causing Urinary Tract Infections and Its Antibiotic Susceptibility Pattern at Tertiary Hospital in Al-Baha Region, Saudi Arabia: A Retrospective Study. *J Pharm Bioallied Sci.*, 12 (4) : 449-456.
 4. Belas, A.; Marques, C.; Menezes, J.; da Gama, L.T.; Cavaco-Silva, P.; Pomba, C. (2022): ESBL/pAmpC-Producing *Escherichia coli* Causing Urinary Tract Infections in Non-Related Companion Animals and Humans. *Antibiotics*, 11, 559-574.
 5. Chang, S.K., Lo, D.Y., Wei, H.W. and Kuo, H.C. (2015): Antimicrobial resistance of *Escherichia coli* isolates from canine urinary tract infections. *J. Vet. Med. Sci.*, 77(1): 59-65.
 6. CLSI (2018): Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th Ed. CLSI standard M02. Wayne, PA: Clinical and Laboratory Standards Institute. ASM Journals. *Journal of Clinical Microbiology* Vol. 59, No. 12.
 7. Colom K, PérezJ, Alonso R, Fernández-Aranguiz A, LariñoE, Cisterna R. (2003): Simple and reliable multiplex PCR assay for detection of blaTEM, blaSHV and blaOXA-1 genes in Enterobacteriaceae. *FEMS Microbiology Letters*, 223: 147-151.
 8. Robicsek, A., Strahilevitz, J., Jacoby, G. A., Macielag, M., Abbanat, D., Park, C. H., Bush, K. and Hooper, D. C. (2006): Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat. Med.* 12: 83–88.
 9. Dorsch, R.; Von Vopelius-Feldt, C. and Wolf G. (2016): Urinary tract infections in cats. Prevalence of comorbidities and bacterial species, and determination of antimicrobial susceptibility to commonly used antimicrobial agents. *Tierarzt Prax Ausg K Kleintiere Heimtiere*,44(4):227–236.
 10. Fonseca, J. D.; Mavrides, D. E.; Graham, P. A. and McHugh T. D., (2021): Results of urinary bacterial cultures and antibiotic susceptibility testing of dogs and cats in the UK. *J. Small Animal Practice* 31 August ,62(12): 1085-1091.
 11. Ghavide, M.; Gholamhosseini-Moghadam,T.; Nourian, K. and Ghazvini1, K.(2020): Virulence factors analysis and antibiotic resistance of uropathogenic *Escherichia coli* isolated from patients in northeast of Iran. *Iran. J. Microbiol.*; 12(3): 223–230.
 12. Harada, K.; Niina, A. and Nakai, Y. (2012): Prevalence of antimicrobial resistance in relation to virulence genes and phylogenetic origins among uropathogenic *Escherichia coli* isolates from dogs and cats in Japan. *Am. J. Vet. Res.*, 73: 409–417.
 13. ISO 16649-2: (2001): Microbiology of food and animal feeding stuffs -Horizontal method for the enumeration of _-glucuronidase-positive *Escherichia coli* :- Colony-count technique at 44 °C using 5-bromo-4-chloro-3-indolyl _- D- glucuronide Part 2.
 14. Jang, J., Hur, H.G., Sadowsky, M.J., Byappanahalli, M.N., Yan, T., Ishii, S. (2017): Environmental *Escherichia coli*: ecology and public health implications-a review. *J. Appl. Microbiol.*, 123(3):570-581.
 15. Liu, X., Liu, H., Li, Y. and Hao, C. (2017): Association between virulence profile and fluoroquinolone resistance in *Escherichia coli* isolated from dogs and cats in China. *Infect. Dev. Ctries.* 11(4): 306-313.
 16. Mahdi, B.M.; Khudhur, H.B. and Abdul-Hussein, M.M. (2020): Bacterial Isolates of Urine and their Susceptibility to Antimicrobials. *Open Access Macedonian Journal of Medical Sciences*, 15; 8(A):84-88.
 17. Markey, B.K.; Leonard, F.C.; Archambault, M.; Cullinane, A. and Maguire, D. (2013): *Clinical Veterinary Microbiology*, 2nd Ed. MOSBY. Elsevier Ltd. Edinburgh London New York Oxford Philadelphia St Louis Sydney Toronto.
 18. McMeekin, C.H.; Hill, K.E.; Gibson, I.R. Bridges J.P. and Benschop, J. (2016): Antimicrobial resistance patterns of bacteria isolated from canine urinary samples submitted to a New Zealand veterinary diagnostic laboratory between 2005–2012. *New Zealand Vet. J.*, 65(2):99–104.
 19. Momtaz, H., Karimian, A., Madani, M., et al. (2013): Uropathogenic *Escherichia coli* in Iran: Serogroup distributions, virulence factors and antimicrobial resistance properties. *Ann. Clin. Microbiol. Antimicrob.*,12:8-17.
 20. Mortazavi - Tabatabaei SA, Ghaderkhani J, Nazari A, Sayehmiri K, Sayehmiri F, Pakzad I. (2019): Pattern of antibacterial resistance in urinary tract infections: A systematic review and meta-analysis. *Int. J. Prev. Med.*, 10:169- 179.
 21. Moyaert, H., Morrissey, I., de Jong, A., El Garch, F., Klein, U., Ludwig, C., Thiry, J. and Youala, M. (2017): Antimicrobial susceptibility monitoring of bacterial pathogens isolated from urinary tract infections in dogs and cats across Europe: ComPath Results. *Microbial. Drug Resist.*, 23(3):391-403.
 22. Mustapha, M., Goel, P., Kumar, V., DIVYA Agnihotri, D., Kumar, T. and Maan, S. (2019): Isolation of uropathogenic *Escherichia coli* from dogs and molecular detection of chloramphenicol resistance genes. *Haryana Vet.*, 58(1), 66-69.
 23. Nguyen, MC., Woerther, PL., Bouvet, M., Andremont, A., Leclercq, R., Canu, A. (2009): *Escherichia coli* as reservoir for macrolide resistance genes. *Emerging infectious diseases*, 15(10):1648-1656.
 24. Raeispour, M., and Ranjbar, R. (2018): Antibiotic resistance, virulence factors and genotyping of Uropathogenic *Escherichia coli* strains. *Antimicrob. Resist. Infect. Control.*,7:118-125.
 25. Ramirez-Castillo, F. Y.; Moreno-Flores,A.C.; Avelar-Gonzalez ,F.J.; Marquez-Diaz, F.; Harel, J. and Guerrero-Barrera, A.L.(2018): An evaluation of multidrug-resistant *Escherichia coli* isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. *Ann. Clin. Microbiol. Antimicrob.* 17:34-39.
 26. Randall, L.P.; Cooles, S.W.; Osborn, M.K.; Piddock, L.J.V. and Woodward, M.J. (2004): Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of *Salmonella enterica* isolated from humans and animals in the UK. *J. Antimicrobial Chemotherapy*, 53: 208– 216.
 27. Rezazadeh, M.; Baghchesaraei, H. and Peymani, A. (2016): Plasmid-Mediated Quinolone-Resistance (qnr) Genes in Clinical Isolates of *Escherichia coli* Collected from Several Hospitals of Qazvin and Zanjan Provinces, Iran. *Osong Public Health Res. Perspect.*, 7(5): 307–312.

28. Rzewuska, M., Czopowicz, M., KizerwetterSwidia, M., Chrobak, D., Blaszczałk, B. and Binek, M. (2015): Multidrug resistance in *Escherichia coli* strains isolated from infections in dogs and cats in Poland (2007-2013). *Sci. World. J.* 10 (1155): 1-8.
29. Said, A. 1; El-Gamal, M.S.; Mohammed Abu-Elghait, M. 1 and Salem, S.S. (2021): Isolation, Identification and Antibiotic Susceptibility Pattern of Urinary Tract Infection Bacterial Isolates. *Letters in Applied NanoBioScience* •: 10.33263/LIANBS104.28202830
30. Salehi, A.; Davari, K.; Karimoddini, M.; Sanani, M.G.P. (2021): Evaluating the Macrolide Resistance of *Escherichia coli* isolated from the urinary infection and determining the phylogeny Using the ERIC-PCR method. *European J. Molecular & Clinical Medicine* ISSN 2515-8260 Volume 08, Issue 1
31. Setu, S. Kh.; Ibne Sattar, A. N.; Abu Saleh, A.; Roy, C.K.; Ahmed, M.; Muhammadullah, S. and Kabir, M.H. (2016): Study of Bacterial pathogens in Urinary Tract Infection and their antibiotic resistance profile in a tertiary care hospital of Bangladesh. *Bangladesh J. Med. Microbiol.*, 10 (01): 22-26.
32. Windahl, U.; Holst, B.S.; Nyman, A.; Grönlund, U. and Bengtsson, B. (2014): Characterization of bacterial growth and antimicrobial susceptibility patterns in canine urinary tract infections. *BMC Veterinary Research*, 10:217-225.
33. Yadav, SN, Ahmed N, Nath AJ, Mahanta D, Kalita MK (2020): Urinalysis in dog and cat: A review, *Veterinary World*, 13(10): 2133-2141.